- Home
- IMMX vs LPRO Comparison
IMMX vs LPRO Comparison
Compare IMMX & LPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMMX | LPRO |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.9M | 252.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMMX | LPRO |
|---|---|---|
| Price | $5.67 | $1.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $12.00 | $2.83 |
| AVG Volume (30 Days) | ★ 1.3M | 513.2K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,948,000.00 |
| Revenue This Year | N/A | $306.66 |
| Revenue Next Year | N/A | $7.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $0.70 |
| 52 Week High | $7.73 | $6.73 |
Technical Indicators
Market Signals| Indicator | IMMX | LPRO |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 40.46 |
| Support Level | $5.33 | $1.65 |
| Resistance Level | $7.73 | $1.87 |
| Average True Range (ATR) | 0.77 | 0.10 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 48.35 | 4.84 |
Price Performance
Historical ComparisonAbout IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.